Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children

Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Archives of Pediatrics and Adolescent Medicine (Impact Factor: 4.25). 10/2007; 161(9):857-64. DOI: 10.1001/archpedi.161.9.857
Source: PubMed

ABSTRACT To determine the US national prevalence of attention-deficit/hyperactivity disorder (ADHD) and whether prevalence, recognition, and treatment vary by socioeconomic group.
Cross-sectional survey.
Nationally representative sample of the US population from 2001 to 2004.
Eight- to 15-year-old children (N = 3082) in the National Health and Nutrition Examination Survey.
The Diagnostic Interview Schedule for Children (caregiver module) was used to ascertain the presence of ADHD in the past year based on Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) criteria. Prior diagnosis of ADHD by a health professional and ADHD medication use were assessed by caregiver report.
Of the children, 8.7% met DSM-IV criteria for ADHD. The poorest children (lowest quintile) were more likely than the wealthiest (highest quintile) to fulfill criteria for ADHD (adjusted odds ratio [AOR], 2.3; 95% confidence interval [CI], 1.4-3.9). Among children meeting DSM-IV ADHD criteria, 47.9% had a prior diagnosis of ADHD and 32.0% were treated consistently with ADHD medications during the past year. Girls were less likely than boys to have their disorder identified (AOR, 0.3; 95% CI, 0.1-0.8), and the wealthiest children were more likely than the poorest to receive regular medication treatment (AOR, 3.4; 95% CI, 1.3-9.1).
Of US children aged 8 to 15 years, 8.7%, an estimated 2.4 million, meet DSM-IV criteria for ADHD. Less than half of children meeting DSM-IV criteria report receiving either a diagnosis of ADHD or regular medication treatment. Poor children are most likely to meet criteria for ADHD yet are least likely to receive consistent pharmacotherapy.


Available from: Tanya E Froehlich, Apr 18, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent media coverage has highlighted discrepancies in the entitlements of children to free ADHD medication across the country. The Department of Health has since ruled that children with ADHD under 16 are entitled to receive free medications. This study examines the cost to the State of ADHD medication and implications for universal coverage under the long-term illness (LTI) scheme for under 16s. We estimate a potential cost for universal coverage for under 16s. Drug reimbursement entitlements were explored for children with ADHD. Data were retrieved from the Primary Care Reimbursement Services for the Community Drug Schemes for 2011. The cumulative and percentage-spent on the LTI scheme was calculated. 107,894 (4.4 %) of the 2.4 million State spent on ADHD medicines was under the LTI scheme in 2011. We estimate a potential cost of 8.4 million for costs of ADHD medicines for the state based on current prescribing patterns. There appears to be a significant underutilisation of the LTI scheme affording children free ADHD medication. Public and professional awareness campaigns are required to ensure families get the benefits to which they are entitled, and cost does not become a barrier to treatment adherence and improved outcomes. Leading from this, we propose suggestions for cost-effective prescribing to minimise potential cost implications.
    Irish Journal of Medical Science 02/2015; DOI:10.1007/s11845-015-1263-z · 0.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Attention Deficit Hyperactivity Disorder (ADHD) is associated with hypofunctional medial prefrontal cortex (mPFC) and orbitofrontal cortex (OFC). Methylphenidate (MPH) remediates ADHD, in part, by inhibiting the norepinephrine transporter (NET). MPH also reduces ADHD-like symptoms in Spontaneously Hypertensive Rats (SHRs), a model of ADHD. However, effects of chronic MPH treatment on NET function in mPFC and OFC in SHR have not been reported. In the current study, long-term effects of repeated treatment with a therapeutically relevant oral dose of MPH during adolescence on NET function in subregions of mPFC (cingulate gyrus, prelimbic cortex and infralimbic cortex) and in the OFC of adult SHR, Wistar-Kyoto (WKY, inbred control) and Wistar (WIS, outbred control) rats were determined using in vivo voltammetry. Following local ejection of norepinephrine (NE), uptake rate was determined as peak amplitude (Amax) x first-order rate constant (k-1). In mPFC subregions, no strain or treatment effects were found in NE uptake rate. In OFC, NE uptake rate in vehicle-treated adult SHR was greater than in adult WKY and WIS administered vehicle. MPH treatment during adolescence normalized NE uptake rate in OFC in SHR. Thus, the current study implicates increased NET function in OFC as an underlying mechanism for reduced noradrenergic transmission in OFC, and consequently, the behavioral deficits associated with ADHD. MPH treatment during adolescence normalized NET function in OFC in adulthood, suggesting that the therapeutic action of MPH persists long after treatment cessation and may contribute to lasting reductions in deficits associated with ADHD. Copyright © 2015. Published by Elsevier B.V.
    Journal of Neuroscience Methods 02/2015; DOI:10.1016/j.jneumeth.2015.02.002 · 1.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The 1432 participants were mainly male (74.8%), aged 10–18 (M = 15.82, SD = 1.59) African-American juveniles arrested in a moderately sized Mid-Atlantic city in the USA. Using Conners Comprehensive Behavior Rating Scales-Self Report scores, two parallel cluster analyses were developed, one based on Attention Deficit/Hyperactivity Disorder (ADHD) symptom frequency and another based on ADHD symptom count. ADHD profiles were good predictors of functioning in both cluster solutions, as evidenced by differences in other indices of mental health (e.g. symptoms of depression) and academic problems across and between clusters. Further inquiry showed that ADHD symptom frequency clustering had a larger effect on functioning than symptom count clustering. Results also corroborated with the hypothesis that ADHD is best conceptualized as a single disorder that differs in symptom elevation. Higher rates of severe ADHD symptoms were identified in females than males, but no differences were found across age or socioeconomic groups.
    Journal of Forensic Psychiatry and Psychology 10/2013; 24(5):570-593. DOI:10.1080/14789949.2013.823218 · 0.88 Impact Factor